title: Role of sucralfate in gastrointestinal diseases.
abstract: Sucralfate is a cytoprotective drug widely used in clinical practice to prevent or treat several gastrointestinal diseases such as gastro-esophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. Sucralfate is a safe and well tolerated drug, as demonstrated by the quite complete lack of side effects and it is, for this reason, one of the most important therapeutic choices in the management of acid related diseases during pregnancy. Moreover, sucralfate has recently been shown to be useful in non-acid related gastrointestinal disease as well. In fact, sucralfate has also been administered topically in patients with radiation-induced mucosal procto-sigmoiditis or ulcerative colitis with surprising results. The drug is actually able to form a physical barrier between epithelium and damaging agents (-bile salts, drugs, refluxate...). Moreover, sucralfate increases the local levels of fibroblast growth factors and induces a rise in the mucosal concentration of prostaglandins which are considered important factors in mucosal healing. The aim of this paper is to describe the current and probably forthcoming uses of sucralfate in the field of gastrointestinal disorders. Moreover, we investigate the role of sucralfate as a reliable means to prevent the occurrence of reflux-like symptoms after Helicobacter pylori eradication and in the management of Helicobacter pylori negative patients affected by non-ulcer dyspepsia.
authors.affiliation: Internal Medicine Deptartment, Gemelli Hospital, Catholic University of Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Candelli
authors.forename: E
authors.initials: E
authors.lastname: Carloni
authors.forename: A
authors.initials: A
authors.lastname: Armuzzi
authors.forename: G
authors.initials: G
authors.lastname: Cammarota
authors.forename: V
authors.initials: V
authors.lastname: Ojetti
authors.forename: G
authors.initials: G
authors.lastname: Pignataro
authors.forename: A
authors.initials: A
authors.lastname: Santoliquido
authors.forename: R
authors.initials: R
authors.lastname: Pola
authors.forename: E
authors.initials: E
authors.lastname: Pola
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
authors.forename: A
authors.initials: A
authors.lastname: Gasbarrini
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D013392:Sucralfate / Q000627:therapeutic use*
chemical_list: D000897:Anti-Ulcer Agents; D005765:Gastrointestinal Agents; D013392:Sucralfate